CPT2 and metabolic dysfunction-associated steatotic liver disease: In another study, Yao et al. reported that carnitine palmitoyltransferase-2 (CPT-2) dysfunction and inactivity could be the key event in the novel pathogenesis for NAFLD/NASH in the hepatocarcinogenesis pathway and its potential to become a potential therapeutic target of this disease [43] (Table 1 and Table 2).